Neuroendocrine testing in community patients with heart disease: Plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 64, Issue 7, 2004, Pages 619-628

  Nielsen, Olav Wendelboe ^a   Rasmussen, V ^b   Christensen, N J ^c   Hansen, J F ^c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

24 h monitoring of blood pressure; 24 h monitoring of electrocardiogram; Catecholamines; Congestive heart failure; Heart rate variability; Mortality; Natriuretic peptide

Indexed keywords

ADRENALIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CREATININE; N TERMINAL PROATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; UNCLASSIFIED DRUG; UREA;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CATECHOLAMINE BLOOD LEVEL; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE MARKER; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART DISEASE; HEART PERFORMANCE; HEART RATE VARIABILITY; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE SYSTEM; PHYSICAL EXAMINATION; PREMATURE VENTRICULAR CAPTURE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; THORAX RADIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UREA BLOOD LEVEL; VALVULAR HEART DISEASE;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; COMMUNITY HEALTH SERVICES; EPINEPHRINE; FEMALE; HEART DISEASES; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NOREPINEPHRINE; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 7044237321     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410002878     Document Type: Article

References (23)

1. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350(9088): 1349-53.
2. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-6.
3. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002; 4: 11-22.
4. Retterstol L, Djurovic S, Bohn M, Bakken A, Erikssen J, Berg K. Plasma N-terminal pro-atrial natriuretic peptide predicts death after premature myocardial infarction, but not as well as radionuclide ejection fraction. A ten-year follow-up study. Scand Cardiovasc J 2001; 35: 373-8.
5. Smith JA, Bruusgaard D, Bodd E, Hall C. Relations between medical history, clinical findings and plasma N-terminal proatrial natriuretic peptide in patients in primary health care. Eur J Heart Fail 2001; 3: 307-13.
6. Burger AJ, Aronson D. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. J Card Fail 2001; 7: 122-8.
7. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Nielsen JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-6.
8. Nielsen OW, Hilden J, Larsen CT, Hansen JF. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 2001; 86: 172-8.
9. Rose GA, Blackburn H. Cardiovascular survey methods. Monograph Series World Health Organisation 1968; 56: 1-188.
10. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985; 38: 733-9.
11. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. Br Med J 2000; 320(7229): 220-4.
12. Christensen NJ, Vestergaard P, Sorensen T, Rafaelsen OJ. Cerebrospinal fluid adrenaline and noradrenaline in depressed patients. Acta Psychiatr Scand 1980; 61: 178-82.
13. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
14. Bibbins-Domingo KPM, Ansari MM, Schiller NBM, Massie BM, Whooley MAM. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul Study. Circulation 2003; 108: 2987-92.
15. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-20.
16. Schirmer H, Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. Eur Heart J 1999; 20: 755-63.
17. Gerber IL, Stewart RAH, Legget ME, West TM, French RL, Sutton TM, Yandle TG, French JK, Richards AM, White HD. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107: 1884-90.
18. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, Pacher R. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002; 23: 886-91.
19. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC Jr. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002; 8: 149-54.
20. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, Rousseau MF. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 2000; 6: 201-7.
21. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, Sawaki M, Fujii M, Horie H, Sugimoto Y, Kinoshita M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-807.
22. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.
23. McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail 2002; 4: 479-83.